| Serial Number | 90024830 |
| Word Mark | HOLOGRAPHIC NEXT GENERATION GENOMIC DNA SEQUENCING |
| Filing Date | Sunday, June 28, 2020 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Wednesday, August 23, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| In Another Form Statement | The mark was first used anywhere in a different form other than that sought to be registered at least as early as 10/20/2006 |
| In Another Form Statement | The mark was first used in commerce in a different form other than that sought to be registered at least as early as 09/08/2007 |
| Goods and Services | DNA analysis services for scientific research purposes; DNA analysis services to determine paternity; DNA screening for scientific research purposes; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Genome amplification; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of new technology for others in the field of genetics; Development of new technology for others in the field of genomics; Development of new technology for others in the field of holographic genome sequencing; Development of new technology for others in the field of holographic genome testing; Development of new technology for others in the field of gene splicing; Development of new technology for others in the field of holographic gene splicing; Development of new technology for others in the field of decoding genes; Development of new technology for others in the field of decoding genomes; Development of new technology for others in the field of decoding DNA; Development of new technology for others in the field of holographic genome decoding; Development of new technology for others in the field of holographic genomic decoding; Development of new technology for others in the field of genome decoding holography; Development of new technology for others in the field of genomic DNA sequencing; Development of new technology for others in the field of holographic genomic DNA sequencing; Development of new technology for others in the field of genomic DNA sequencing holography; Drug, alcohol and DNA screening for forensic research purposes; Providing information in the field of plant genetics research resources; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing scientific research information in the field of genetics; Providing scientific research information in the field of genomics; Providing scientific research information in the field of holographic genome sequencing; Providing scientific research information in the field of holographic genome testing; Providing scientific research information in the field of gene splicing; Providing scientific research information in the field of holographic gene splicing; Providing scientific research information in the field of decoding genes; Providing scientific research information in the field of decoding genomes; Providing scientific research information in the field of decoding DNA; Providing scientific research information in the field of holographic genome decoding; Providing scientific research information in the field of holographic genomic decoding; Providing scientific research information in the field of genome decoding holography; Providing scientific research information in the field of genomic DNA sequencing; Providing scientific research information in the field of holographic genomic DNA sequencing; Providing scientific research information in the field of genomic DNA sequencing holography; Scientific research consulting in the field of genetics; Scientific research consulting in the field of genomics; Scientific research consulting in the field of holographic genome sequencing; Scientific research consulting in the field of holographic genome testing; Scientific research consulting in the field of gene splicing; Scientific research consulting in the field of holographic gene splicing; Scientific research consulting in the field of decoding genes; Scientific research consulting in the field of decoding genomes; Scientific research consulting in the field of decoding DNA; Scientific research consulting in the field of holographic genome decoding; Scientific research consulting in the field of holographic genomic decoding; Scientific research consulting in the field of genome decoding holography; Scientific research consulting in the field of genomic DNA sequencing; Scientific research consulting in the field of holographic genomic DNA sequencing; Scientific research consulting in the field of genomic DNA sequencing holography; Scientific research in the field of genetics and genetic engineering; Scientific research in the field of genetics; Scientific research in the field of genomics; Scientific research in the field of holographic genome sequencing; Scientific research in the field of holographic genome testing; Scientific research in the field of gene splicing; Scientific research in the field of holographic gene splicing; Scientific research in the field of decoding genes; Scientific research in the field of decoding genomes; Scientific research in the field of decoding DNA; Scientific research in the field of holographic genome decoding; Scientific research in the field of holographic genomic decoding; Scientific research in the field of genome decoding holography; Scientific research in the field of genomic DNA sequencing; Scientific research in the field of holographic genomic DNA sequencing; Scientific research in the field of genomic DNA sequencing holography; Structural and functional analysis of genomes; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 24, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | Tampa, FL 33615 |
| Event Date | Event Description |
| Wednesday, August 23, 2023 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Wednesday, August 23, 2023 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Wednesday, August 23, 2023 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Tuesday, May 9, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, May 9, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, May 9, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, April 10, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, April 10, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, April 8, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, April 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, April 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, January 8, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, January 8, 2023 | NON-FINAL ACTION E-MAILED |
| Sunday, January 8, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, December 6, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, December 6, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 6, 2022 | ASSIGNED TO LIE |
| Tuesday, October 18, 2022 | NOTICE OF REVIVAL - E-MAILED |
| Monday, October 17, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, October 17, 2022 | PETITION TO REVIVE-GRANTED |
| Monday, October 17, 2022 | TEAS PETITION TO REVIVE RECEIVED |
| Friday, August 19, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Thursday, August 18, 2022 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Thursday, August 18, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Friday, February 4, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, February 4, 2022 | NON-FINAL ACTION E-MAILED |
| Friday, February 4, 2022 | NON-FINAL ACTION WRITTEN |
| Saturday, January 8, 2022 | NOTICE OF REVIVAL - E-MAILED |
| Friday, January 7, 2022 | PETITION TO REVIVE-GRANTED |
| Friday, January 7, 2022 | TEAS PETITION TO REVIVE RECEIVED |
| Monday, November 8, 2021 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Monday, November 8, 2021 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Monday, April 26, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 26, 2021 | NON-FINAL ACTION E-MAILED |
| Monday, April 26, 2021 | NON-FINAL ACTION WRITTEN |
| Monday, March 22, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, March 22, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 22, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, September 22, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, September 22, 2020 | NON-FINAL ACTION E-MAILED |
| Tuesday, September 22, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 16, 2020 | ASSIGNED TO EXAMINER |
| Friday, July 24, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, July 1, 2020 | NEW APPLICATION ENTERED |